Mauna Kea Technologies SAS announced that the company's Board of Directors appointed new board member Gilles Brisson to the role of Chairman of the Board. Mr. Gilles Brisson has served in various roles during his 20-year tenure at Rhone-Poulenc Rorer, including Senior Vice-President of Corporate Development. He led Aventis' French pharma business from 1999 to 2003 as President and CEO. Then he became Senior Vice President of Europe for Aventis and Sanofi-aventis. Mr. Gilles Brisson has been Chairman of the Supervisory Board of Innate Pharma since 2007 and since 2009 of Ethypharm. Mr. Gilles Brisson replaces Mr. Albert Waxman in the Chairman role and is filling the Director seat previously held by Mr. Nicolas Mulliez who is stepping down from the Board for personal reasons. Mr. Waxman remains a Director. Mr. Gilles Brisson's appointment as a Director is subject to shareholder approval at the next Shareholders' Meeting scheduled for June 15, 2012.